review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | I Barberis | |
M Martini | |||
F Ansaldi | |||
V Faccio | |||
C Paganino | |||
C Trucchi | |||
V Tisa | |||
P2860 | cites work | Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis | Q26751854 |
Influenza-associated hospitalizations in the United States | Q29619463 | ||
Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature | Q33649395 | ||
The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model | Q33721397 | ||
Epidemiology and pathogenesis of influenza | Q33907890 | ||
Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies | Q34451202 | ||
Vaccine recommendations for children and youth for the 2014/2015 influenza season | Q34453977 | ||
Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season | Q34614814 | ||
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years | Q34862926 | ||
4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany | Q35200964 | ||
Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom | Q35821862 | ||
Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis. | Q35886955 | ||
Retrospective public health impact of a quadrivalent influenza vaccine in the United States. | Q35995259 | ||
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years | Q36846234 | ||
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015 | Q37027049 | ||
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children | Q37037095 | ||
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries | Q37130821 | ||
The rationale for quadrivalent influenza vaccines | Q37976542 | ||
The evolving history of influenza viruses and influenza vaccines | Q38136296 | ||
Influenza B viruses: not to be discounted | Q38584342 | ||
Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines. | Q38660898 | ||
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children | Q40291541 | ||
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results | Q40357312 | ||
Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K. | Q41026843 | ||
Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. | Q41042952 | ||
Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia | Q41206726 | ||
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season | Q41510283 | ||
Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. | Q42181750 | ||
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults | Q42271180 | ||
Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. | Q43207722 | ||
Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season | Q46159620 | ||
Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season | Q73437339 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
P433 | issue | 1 | |
P921 | main subject | influenza | Q2840 |
influenza vaccine | Q383260 | ||
influenza A virus | Q834390 | ||
Influenza B virus | Q1089532 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | E28-33 | |
P577 | publication date | 2016-01-01 | |
P1433 | published in | Journal of preventive medicine and hygiene | Q26842091 |
P1476 | title | Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden | |
P478 | volume | 57 |
Q39397313 | A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus |
Q55094530 | A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers. |
Q64246989 | Awareness and acceptance of H1N1 vaccination among physicians: Experience of 2017 vaccination campaign |
Q89720566 | Better influenza vaccines: an industry perspective |
Q89965369 | Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics |
Q92360676 | Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza |
Q64245823 | Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016 |
Q56536297 | Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View |
Q57210543 | Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea |
Q92023401 | Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity |
Q37669436 | Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy. |
Q28079669 | History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines |
Q91989762 | Identification of Rare Adverse Events with Year-varying Reporting Rates for FLU4 Vaccine in VAERS |
Q52655883 | Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy. |
Q52599675 | Novel Platforms for the Development of a Universal Influenza Vaccine. |
Q38375170 | Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial |
Q55038946 | Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study. |
Q88642245 | Sustainable vaccine development: a vaccine manufacturer's perspective |
Q94545406 | Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives |